RMD Jun 2024 250.000 call
- Yahoo Finance
How Lilly is joining Novo in the crusade to circumvent Medicare's block on weight loss drugs
The leaders in the business of weight-loss drugs, Novo Nordisk and Eli Lilly, are fighting on a number of fronts to get Medicare officials to pay for the popular medicines.
- Yahoo Finance Video
Eli Lilly seeks to expand Zepbound use to treat sleep apnea
Eli Lilly (LLY) is reporting success in the use of Zepbound — one of the pharmaceutical giant's landmark GLP-1 weight-loss drugs — to treat sleep apnea. Yahoo Finance Health Reporter Anjalee Khemlani joins The Morning Brief to discuss Eli Lilly's filing for approval from the US Food and Drug Administration (FDA) for this use case and how it may affect makers of CPAP (Continuous Positive Airway Pressure) sleep devices, such as Philips (PHG) and ResMed (RMD). For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.
- Investor's Business Daily
Eli Lilly's Weight-Loss Drug Takes Down ResMed, Inspire Medical — Again
ResMed stock and Inspire Medical Systems stock tumbled Monday after Eli Lilly said its weight-loss drug reduced sleep apnea events.
